JOURNAL OF CHEMOTHERAPY

Scope & Guideline

Exploring Breakthroughs in Infectious Disease Treatment

Introduction

Explore the comprehensive scope of JOURNAL OF CHEMOTHERAPY through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore JOURNAL OF CHEMOTHERAPY in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1120-009x
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1989 to 2024
AbbreviationJ CHEMOTHERAPY / J. Chemother.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The Journal of Chemotherapy focuses on advancing the understanding and treatment of infectious diseases and cancer through innovative research, clinical trials, and pharmacological studies. The journal emphasizes the importance of chemotherapy and its related fields, including drug resistance, pharmacokinetics, and treatment efficacy.
  1. Chemotherapy Efficacy and Safety:
    Research on the effectiveness and safety profiles of chemotherapy regimens across various cancers, including comparative effectiveness studies of different drug combinations.
  2. Pharmacokinetics and Drug Dosing:
    Studies focusing on the pharmacokinetics of chemotherapeutic agents and antibiotics, including population pharmacokinetic modeling and dosing strategies tailored for specific patient populations.
  3. Drug Resistance Mechanisms:
    Investigation of mechanisms underlying drug resistance in cancer and infectious diseases, including studies on genetic polymorphisms and the role of non-coding RNAs.
  4. Clinical Trials and Real-World Evidence:
    Publication of findings from clinical trials and real-world studies that provide insights into treatment outcomes, adverse effects, and the clinical management of patients receiving chemotherapy.
  5. Infectious Disease Management:
    Research addressing the management of infectious diseases, particularly focusing on antibiotic resistance, treatment strategies, and the role of novel antimicrobial agents.
The Journal of Chemotherapy is adapting to contemporary challenges in oncology and infectious disease management, with several emerging themes reflecting significant shifts in research focus and clinical practice.
  1. Immunotherapy Combinations:
    There is a growing emphasis on studies exploring the combination of immunotherapy with traditional chemotherapy, reflecting the increasing importance of immunotherapeutic strategies in cancer treatment.
  2. Pharmacogenomics and Personalized Medicine:
    Research on pharmacogenomics is gaining traction, as studies investigate how genetic variations affect drug metabolism and response, leading to more personalized chemotherapy regimens.
  3. Antimicrobial Stewardship and Resistance Management:
    An increased focus on antimicrobial stewardship programs and the management of multi-drug resistant pathogens highlights the urgent need for responsible antibiotic use in clinical settings.
  4. Real-World Evidence and Outcomes Research:
    Emerging trends include the collection and analysis of real-world data to assess treatment efficacy and safety, providing more comprehensive insights into patient outcomes outside of controlled clinical trials.
  5. Targeted Therapies and Novel Agents:
    Research into targeted therapies and the development of novel agents is on the rise, as the field shifts towards more specific and effective treatment options for various malignancies.

Declining or Waning

While the Journal of Chemotherapy continues to publish a wide range of impactful research, certain themes appear to be declining in prominence over recent years. These waning scopes indicate shifts in research focus or changes in treatment paradigms.
  1. Traditional Chemotherapy Alone:
    There is a noticeable decline in studies focusing solely on traditional chemotherapy regimens without combination therapies or novel agents, as the field increasingly emphasizes integrated approaches involving immunotherapy and targeted therapy.
  2. Single-Agent Studies:
    Research dedicated to single-agent chemotherapy efficacy is becoming less common, with a trend towards combination therapies that leverage synergistic effects for improved patient outcomes.
  3. Basic Science Research without Clinical Relevance:
    Basic science papers that do not translate into clinical applications or trials are less frequently published, reflecting a shift towards more clinically relevant research that addresses immediate patient care challenges.
  4. Older Antibiotic Classes:
    Research focusing on older classes of antibiotics is decreasing, as new agents and combination therapies gain attention due to rising antibiotic resistance and the need for more effective treatment strategies.

Similar Journals

Microbial Drug Resistance

Advancing the Fight Against Antibiotic Resistance
Publisher: MARY ANN LIEBERT, INCISSN: 1076-6294Frequency: 10 issues/year

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

MOLECULAR CANCER THERAPEUTICS

Elevating the standards of cancer therapeutics.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1535-7163Frequency: 12 issues/year

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

CPT-Pharmacometrics & Systems Pharmacology

Transforming pharmacology with cutting-edge insights.
Publisher: WILEYISSN: 2163-8306Frequency: 12 issues/year

CPT-Pharmacometrics & Systems Pharmacology, published by WILEY, is a leading open access journal dedicated to advancing the fields of pharmacometrics and systems pharmacology. Since its inception in 2012, it has established itself as a vital resource for researchers and practitioners, boasting a remarkable impact factor and occupying prestigious Q1 quartiles in categories such as Cardiology and Cardiovascular Medicine, Modeling and Simulation, and Pharmacology (Medical). The journal covers a broad spectrum of topics aimed at enhancing the understanding of drug development, efficacy, and patient safety through innovative modeling and simulation approaches. With its consistent ranking in the top tiers of its field, CPT-Pharmacometrics & Systems Pharmacology provides invaluable insights and fosters scholarly dialogue among its audience, including researchers, educators, and students. The journal is accessible to all, promoting knowledge dissemination and collaborative growth in the pharmacology community.

INDIAN JOURNAL OF PHARMACOLOGY

Innovating drug action insights to enhance therapeutic practices.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0253-7613Frequency: 6 issues/year

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.

Antibiotics-Basel

Transforming knowledge into action against infectious threats.
Publisher: MDPIISSN: 2079-6382Frequency: 12 issues/year

Antibiotics-Basel is a prestigious multidisciplinary journal published by MDPI, dedicated to advancing the field of antibiotic research and management. Since its inception in 2012 as an Open Access publication, the journal has established itself as a vital resource for researchers and professionals, offering an accessible platform for the dissemination of innovative findings in Biochemistry, Infectious Diseases, Microbiology, and Pharmacology. With a solid impact in its category, Antibiotics-Basel holds a Q1 ranking in critical areas such as Pharmacology and Pharmacology, Toxicology and Pharmaceutics, making it an influential journal in its field. The journal publishes high-quality research articles, reviews, and communications that are essential for advancing our understanding of antibiotic mechanisms, resistance, and therapeutic applications. Researchers are invited to submit their manuscript to contribute to this growing body of knowledge and collaborate in the fight against antibiotic resistance and infectious diseases.

JOURNAL OF CLINICAL PHARMACOLOGY

Innovating Insights in Clinical Pharmacology
Publisher: WILEYISSN: 0091-2700Frequency: 12 issues/year

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Unveiling Innovations in Drug Action and Therapeutics
Publisher: SPRINGERISSN: 0028-1298Frequency: 12 issues/year

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is a prestigious journal published by SPRINGER, focusing on the dynamic fields of pharmacology and toxicology. With an ISSN of 0028-1298 and an E-ISSN of 1432-1912, this esteemed publication has been a staple in the scientific community since its inception in 1969, continuing to wield influence with a convergence of research that reaches through 2024. Ranked in the Q2 category for both medicine and pharmacology, it stands at an impressive 111th out of 313 in the Scopus rankings for pharmacology, reflecting its significant impact in the field. Though not offering open access, the journal remains a vital resource for researchers, professionals, and students seeking to explore groundbreaking studies and advancements in pharmacological science. With its high standards and comprehensive coverage, NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is essential reading for those dedicated to understanding the mechanisms of drug action and the complexities of therapeutic interventions.

International Journal of Antimicrobial Agents

Leading the Charge in Antimicrobial Research and Development
Publisher: ELSEVIERISSN: 0924-8579Frequency: 12 issues/year

International Journal of Antimicrobial Agents, published by Elsevier, stands as a premier platform in the fields of Infectious Diseases, Microbiology, and Medical Pharmacology. With an impressive impact factor and ranked in the Q1 category across multiple medical disciplines in 2023, this journal is recognized for its contribution to advancing knowledge and understanding in the efficacy and safety of antimicrobial treatments. Its comprehensive scope from 1991 to 2024 allows for the publishing of original research, reviews, and commentary on pressing issues related to antimicrobial resistance, treatment strategies, and pharmacological innovations. With a strong emphasis on high-quality research as reflected in its Scopus rankings, the journal is an essential resource for researchers, clinicians, and students dedicated to improving patient outcomes in the face of evolving microbiological challenges. Engage with the latest findings and methodologies through this vital academic resource, available in print and online, from the heart of the Netherlands.

Clinical Pharmacology in Drug Development

Advancing pharmaceutical science for a healthier tomorrow.
Publisher: WILEYISSN: 2160-7648Frequency: 6 issues/year

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Connecting researchers and practitioners in the world of pharmacology.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.